Literature DB >> 31321589

Factors related to the quality of life in patients with bone metastases.

Yusuke Shinoda1, Ryoko Sawada2,3, Futaba Yoshikawa2,3, Takahiro Oki2,3, Toshihide Hirai3, Hiroshi Kobayashi3, Ko Matsudaira4, Hiroyuki Oka4, Sakae Tanaka3, Hirotaka Kawano5, Nobuhiko Haga2.   

Abstract

Treatment for bone metastases aims to preserve patients' quality of life (QOL). Therefore, assessment of patients' reported QOL is important, especially in this field. This cross-sectional study sought to investigate the clinical factors of QOL in patients with bone metastasis in different cancer settings, at any treatment status, and examined the effect of these factors on systemic symptoms and psychological disorders. This study was conducted by a multidisciplinary team for bone metastases at a university hospital in Japan. One-hundred seventy-four patients who could complete the self-report questionnaires were selected. The questionnaire included the EQ-5D, EORTC QLQ-C15-PAL, BM22, and K6 distress scale. We obtained clinical data on tumor progression, bone metastasis, pain, and ECOG-PS. The mean (SD) EQ-5D score was 0.58 (0.24), which was lower than that of the general Japanese and US population (0.85). Skeletal-related events (SREs), pain, and ECOG-PS were significantly related to lower EQ-5D scores in the multivariable analysis (p < 0.01), whereas primary lesion or expected prognosis at the first examination was not. These three factors were also related to systemic symptoms and emotional functioning. Radiologically lytic bone metastasis and lower limb/acetabular metastases were related to SREs and ECOG-PS, respectively. In conclusion, for improving the QOL of patients with bone metastases, we should focus on SRE prevention, treatment for pain, and modifying ADL, and a multidisciplinary team might be useful.

Entities:  

Keywords:  Bone metastasis; Multidisciplinary approach; Pain; Performance status; Quality of life; Skeletal-related events

Mesh:

Year:  2019        PMID: 31321589     DOI: 10.1007/s10585-019-09983-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  25 in total

1.  The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.

Authors:  Edward Chow; Amanda Hird; Galina Velikova; Colin Johnson; Linda Dewolf; Andrea Bezjak; Jackson Wu; Jesmin Shafiq; Orhan Sezer; Dimitrios Kardamakis; Yvette van der Linden; Brigette Ma; Monica Castro; Palmira Foro Arnalot; Sam Ahmedzai; Mark Clemons; Peter Hoskin; Albert Yee; Michael Brundage; Andrew Bottomley
Journal:  Eur J Cancer       Date:  2008-12-25       Impact factor: 9.162

2.  Predictors of quality of life in oncology outpatients with pain from bone metastasis.

Authors:  Tone Rustøen; Torbjørn Moum; Geraldine Padilla; Steven Paul; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2005-09       Impact factor: 3.612

Review 3.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

Authors:  R E Coleman
Journal:  Cancer Treat Rev       Date:  2001-06       Impact factor: 12.111

Review 4.  Incidence, location, and diagnostic evaluation of metastatic bone disease.

Authors:  W D Hage; A J Aboulafia; D M Aboulafia
Journal:  Orthop Clin North Am       Date:  2000-10       Impact factor: 2.472

Review 5.  Surgical treatment of bone metastasis: indications and outcomes.

Authors:  Jun Manabe; Noriyoshi Kawaguchi; Seiichi Matsumoto; Taisuke Tanizawa
Journal:  Int J Clin Oncol       Date:  2005-04       Impact factor: 3.402

6.  The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care.

Authors:  Mogens Groenvold; Morten Aa Petersen; Neil K Aaronson; Juan I Arraras; Jane M Blazeby; Andrew Bottomley; Peter M Fayers; Alexander de Graeff; Eva Hammerlid; Stein Kaasa; Mirjam A G Sprangers; Jakob B Bjorner
Journal:  Eur J Cancer       Date:  2005-09-12       Impact factor: 9.162

7.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

8.  Persistent benefits of rehabilitation on pain and life quality for nonambulatory patients with spinal epidural metastasis.

Authors:  Robert L Ruff; Suzanne S Ruff; Xiaofeng Wang
Journal:  J Rehabil Res Dev       Date:  2007

9.  Short screening scales to monitor population prevalences and trends in non-specific psychological distress.

Authors:  R C Kessler; G Andrews; L J Colpe; E Hiripi; D K Mroczek; S L T Normand; E E Walters; A M Zaslavsky
Journal:  Psychol Med       Date:  2002-08       Impact factor: 7.723

10.  Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?

Authors:  Vassilios Vassiliou; Christine Kalogeropoulou; Theodoros Petsas; Michael Leotsinidis; Dimitrios Kardamakis
Journal:  Clin Exp Metastasis       Date:  2007-02-13       Impact factor: 4.510

View more
  3 in total

Review 1.  Rehabilitation in Advanced Cancer Patients with Bone Metastases and Neural Compromise: Current Status and Future Directions.

Authors:  Cho Rong Bae; Ma Nessa Gelvosa; Jae Yong Jeon
Journal:  Curr Oncol Rep       Date:  2022-04-01       Impact factor: 5.945

2.  Effectiveness of Rehabilitation for Cancer Patients with Bone Metastasis.

Authors:  Maki Itokazu; Yuji Higashimoto; Masami Ueda; Kazushi Hanada; Saori Murakami; Kanji Fukuda
Journal:  Prog Rehabil Med       Date:  2022-05-18

3.  A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers.

Authors:  Satoe Okuma; Yuhei Matsuda; Yoshiki Nariai; Masaaki Karino; Ritsuro Suzuki; Takahiro Kanno
Journal:  Cancers (Basel)       Date:  2020-05-12       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.